Who are Eflornithine plus Sulindac's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eflornithine-plus-sulindac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Eflornithine plus Sulindac — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eflornithine plus Sulindac (Eflornithine plus Sulindac) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyamine synthesis inhibitor + NSAID combination. Area: Oncology.

phase 3 Polyamine synthesis inhibitor + NSAID combination Ornithine decarboxylase (ODC); COX-1/COX-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Eflornithine plus Sulindac (Eflornithine plus Sulindac) — Cancer Prevention Pharmaceuticals, Inc.. Eflornithine inhibits polyamine synthesis while sulindac acts as a non-selective NSAID to reduce inflammation and promote apoptosis, together targeting colorectal cancer prevention.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eflornithine plus Sulindac TARGET	Eflornithine plus Sulindac	Cancer Prevention Pharmaceuticals, Inc.	phase 3	Polyamine synthesis inhibitor + NSAID combination	Ornithine decarboxylase (ODC); COX-1/COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyamine synthesis inhibitor + NSAID combination class)

Cancer Prevention Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eflornithine plus Sulindac — Competitive Intelligence Brief. https://druglandscape.com/ci/eflornithine-plus-sulindac. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab